Ofichem has brought its brands - Ofichem BV, Ofipharma, Ofimedicine, Labatorium Ofichem, Ofichem Uppsala, and Avivia - together as one family-owned CDMO and pharmaceutical supplier.
Daniel Pfeffer, Director of Oligonucleotide Production at Bachem shares why CDMO innovation is key to advancing next-generation oligonucleotide therapies.
Vetter, a Contract Development and Manufacturing Organisation (CDMO), receives recognition as CDMO of the year in the category “Finished Dose” of the 2026 CDMO Leadership Awards.
FUJIFILM Biotechnologies, a development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, has announced that it has been named a 2026 CDMO Leadership Awards winner in the category of Most Innovative CDMO.
At this year’s DCAT Week, Olon is outlining its 2026 development plan, aimed at expanding capabilities across its global network, including the United States, India, Italy, and France, through targeted investments and infrastructure upgrades.
The BCMPA – the Association for Contract Manufacturing, Packing, Fulfilment & Logistics – will be exhibiting at this year’s Making Pharmaceuticals & Distributing Pharmaceuticals show highlighting the power of third-party partnerships.
FUJIFILM Biotechnologies, a contract development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, celebrated the grand opening of its expanded site in Teesside, UK on 11th February.
Symeres has announced it has been awarded ISO/IEC 27001 certification, the internationally recognised standard for information security management systems (ISMS).
Lonza and Genetix Biotherapeutics, a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, has announced the extension of their long-term commercial manufacturing agreement.
The third-party outsourcing community will have the chance to learn about and discuss the latest trends, opportunities and challenges in the industry at this year’s BCMPA Conference, at the Oxford Belfry on 1st April.
Quotient Sciences has extended commercial supply partnership with Ipsen to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
Following his keynote address at the inaugural York and North Yorkshire Life Sciences Forum at York University’s Biotech campus, Chris Allen, CEO of Broughton, sat down with European Pharmaceutical Manufacturer to expand on the conversation.
